Hu Zhiya, Fu Yongxin, Wang Jiawu, Li Yisen, Jiang Qing
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 40000, P.R. China.
Oncol Lett. 2023 Jan 16;25(2):83. doi: 10.3892/ol.2023.13669. eCollection 2023 Feb.
Prostate cancer (PCa) risk in patients with multiple sclerosis (MS) remains to be elucidated. The present study conducted a meta-analysis to assess the relationship between MS and PCa. PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched to identify studies on the PCa risk in patients with MS up to September 2022. A random effects meta-analyses model was performed to estimate the relative risk (RR) and the 95% confidence intervals (CI). All eight studies involving 210,943 patients with MS were identified and included in the meta-analysis. The present study revealed that there was no significant association between MS and the risk of PCa (RR=0.78, 95% CI: 0.56-1.08, P<0.0001). Subgroup analyses verified this conclusion when stratified by regions. However, after adjusting for potential confounders, the findings suggested conflicting results. The current evidence shows that compared with the population control, patients with MS have no relationship with PCa risk and further large samples and long-term trials are needed to verify these results.
多发性硬化症（MS）患者患前列腺癌（PCa）的风险仍有待阐明。本研究进行了一项荟萃分析，以评估MS与PCa之间的关系。检索了PubMed、EMBASE、Web of Science和Cochrane图书馆数据库，以识别截至2022年9月关于MS患者PCa风险的研究。采用随机效应荟萃分析模型来估计相对风险（RR）和95%置信区间（CI）。共识别出八项涉及210943例MS患者的研究，并纳入荟萃分析。本研究表明，MS与PCa风险之间无显著关联（RR = 0.78，95% CI：0.56 - 1.08，P < 0.0001）。按地区分层时，亚组分析验证了这一结论。然而，在对潜在混杂因素进行调整后，研究结果显示出相互矛盾的结果。目前的证据表明，与人群对照组相比，MS患者与PCa风险无关，需要进一步的大样本和长期试验来验证这些结果。
